KRRO (Korro Bio) Earnings per Share (Diluted) : $-9.44 (TTM As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Korro Bio Earnings per Share (Diluted)?

Korro Bio's Earnings per Share (Diluted) for the three months ended in Mar. 2025 was $-2.49. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-9.44.

Korro Bio's EPS (Basic) for the three months ended in Mar. 2025 was $-2.49. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 was $-9.44.

Korro Bio's EPS without NRI for the three months ended in Mar. 2025 was $-2.49. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2025 was $-9.44.

During the past 3 years, the average EPS without NRIGrowth Rate was -50.60% per year.

During the past 4 years, Korro Bio's highest 3-Year average EPS without NRI Growth Rate was -50.60% per year. The lowest was -50.60% per year. And the median was -50.60% per year.

Korro Bio Earnings per Share (Diluted) Historical Data

The historical data trend for Korro Bio's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Korro Bio Earnings per Share (Diluted) Chart

Korro Bio Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Earnings per Share (Diluted)

-2.74

-7.25

-53.08

-9.37

Korro Bio Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Earnings per Share (Diluted)	Get a 7-Day Free Trial						-2.44	-2.43	-2.26	-2.26	-2.49

Competitive Comparison of Korro Bio's Earnings per Share (Diluted)

For the Biotechnology subindustry, Korro Bio's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Korro Bio's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Korro Bio's PE Ratio distribution charts can be found below:

* The bar in red indicates where Korro Bio's PE Ratio falls into.

Save Embed

;

Save Embed

;

Korro Bio Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Korro Bio's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2024 is calculated as

Diluted Earnings Per Share (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-83.581	-	0)	/	8.921
	=	-9.37

Korro Bio's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2025 is calculated as

Diluted Earnings Per Share (Q: Mar. 2025 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-23.387	-	0)	/	9.384
	=	-2.49

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.44

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Korro Bio (NAS:KRRO) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Korro Bio Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Korro Bio's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Korro Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Korro Bio Inc (NAS:KRRO) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

60 First Street, 2nd Floor, Suite 250, Cambridge, MA, USA, 02141

Website

https://www.korrobio.com

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.

Executives

Vineet Agarwal	officer: Chief Financial Officer	C/O KORRO BIO, INC., ONE KENDALL SQUARE, BUILDING 600-700, CAMBRIDGE MA 02139
Scott D Sandell	10 percent owner
Forest Baskett	10 percent owner
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
New Enterprise Associates 17, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Edward T Mathers	10 percent owner	C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Atlas Venture Opportunity Fund Ii, L.p.	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Rick Yang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Paul Edward Walker	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Carmen Chang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
David L. Lucchino	director, officer: President and CEO	C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Atlas Venture Associates Xi, Llc	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Fund Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139